Clinical Report: Aflibercept 8 mg Meets Primary Endpoint in QUASAR

Overview

The QUASAR trial demonstrated that aflibercept 8 mg achieves noninferior vision gains with fewer injections compared to aflibercept 2 mg in treatment-naïve patients with macular edema secondary to retinal vein occlusion, meeting its primary endpoint. At week 36, patients receiving aflibercept 8 mg required an average of 6.1 injections, significantly fewer than the 8.8 injections required by those receiving aflibercept 2 mg.

Background

Retinal vein occlusion (RVO) is a leading cause of vision loss, and effective treatment options are crucial for preserving visual function. Aflibercept, an anti-VEGF therapy, has been a standard treatment, but the frequency of injections can be burdensome for patients. The QUASAR trial evaluates a higher dose of aflibercept to determine if it can reduce treatment frequency while maintaining efficacy.

Data Highlights

Key Findings

• Aflibercept 8 mg achieved noninferior vision gains compared to 2 mg across all RVO subtypes.
• Patients in the 8 mg group required significantly fewer injections (6.1) than those in the 2 mg group (8.8).
• Approximately 70% of patients in the 8 mg group had a last assigned dosing interval of every 12 weeks.
• Both treatment groups showed robust reductions in central retinal thickness.
• Safety outcomes for aflibercept 8 mg were consistent with the established safety profile of aflibercept 2 mg.

Clinical Implications

The findings suggest that aflibercept 8 mg may provide a more convenient treatment regimen for patients with RVO, potentially improving adherence and reducing the burden of frequent injections. Clinicians may consider this option to enhance patient care without compromising visual outcomes, which could lead to better long-term patient management.

Conclusion

Aflibercept 8 mg presents a promising alternative for the treatment of macular edema due to RVO, offering sustained efficacy with fewer injections. Ongoing analysis will further elucidate its long-term benefits, with final data expected after the treatment and monitoring period is completed.

References

1. Retinal Physician, 2025 -- Aflibercept 8 mg Meets Primary Endpoint in QUASAR
2. Retinal Physician, 2025 -- 36-Week Results From QUASAR
3. Retinal Physician, 2025 -- Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension
4. PubMed, 2025 -- Retinal Vein Occlusions Preferred Practice Pattern
5. Regeneron Pharmaceuticals Inc., 2025 -- EYLEA HD® Injection 8 mg Phase 3 Trial Meets Primary Endpoint
6. Retinal Physician — 36-Week Results From QUASAR
7. Effectiveness and safety of anti-VEGF therapies for macular edema in RVO
8. Retinal Vein Occlusions Preferred Practice Pattern® - PubMed
9. EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion | Regeneron Pharmaceuticals Inc.